1. Home
  2. PBK vs SKYE Comparison

PBK vs SKYE Comparison

Compare PBK & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PowerBank Corporation Common Stock

PBK

PowerBank Corporation Common Stock

N/A

Current Price

$0.47

Market Cap

24.3M

Sector

Utilities

ML Signal

N/A

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.28

Market Cap

20.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PBK
SKYE
Founded
N/A
2012
Country
Canada
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.3M
20.0M
IPO Year
2024
2013

Fundamental Metrics

Financial Performance
Metric
PBK
SKYE
Price
$0.47
$0.28
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$15.00
AVG Volume (30 Days)
556.5K
531.0K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.28
52 Week High
$0.86
$4.99

Technical Indicators

Market Signals
Indicator
PBK
SKYE
Relative Strength Index (RSI) 38.32 17.98
Support Level $0.43 N/A
Resistance Level $0.61 $0.87
Average True Range (ATR) 0.04 0.10
MACD 0.01 -0.03
Stochastic Oscillator 18.22 2.96

Price Performance

Historical Comparison
PBK
SKYE

About PBK PowerBank Corporation Common Stock

PowerBank Corp is an independent renewable and clean energy project developer, power producer, and asset operator in Canada and the United States, with the majority of its revenue coming from the United States. The Company operates through two reportable segments: Development and EPC, which involves the development and construction of solar photovoltaic power projects, and IPP Production, which includes the operation of solar power and battery energy storage systems. Corporate and other activities cover operation, maintenance, and repairs. The majority of revenue is generated from the Development and EPC segment.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: